Immutep Limited (NASDAQ:IMMP - Get Free Report)'s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.25 and traded as high as $2.34. Immutep shares last traded at $2.21, with a volume of 111,050 shares trading hands.
Analyst Ratings Changes
Separately, Robert W. Baird cut their target price on shares of Immutep from $7.00 to $6.00 and set an "outperform" rating on the stock in a research note on Thursday, June 27th.
Read Our Latest Research Report on Immutep
Immutep Price Performance
The business has a 50-day moving average of $2.26 and a 200 day moving average of $2.45.
Hedge Funds Weigh In On Immutep
A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Immutep during the second quarter valued at about $26,000. BNP Paribas Financial Markets lifted its stake in Immutep by 15.4% during the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock valued at $82,000 after acquiring an additional 4,700 shares in the last quarter. Virtu Financial LLC lifted its position in shares of Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock valued at $105,000 after purchasing an additional 32,864 shares in the last quarter. XY Capital Ltd bought a new position in shares of Immutep in the second quarter valued at approximately $105,000. Finally, Oracle Investment Management Inc. raised its stake in shares of Immutep by 9.4% during the 1st quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock worth $1,316,000 after purchasing an additional 48,449 shares during the period. 2.32% of the stock is owned by institutional investors and hedge funds.
Immutep Company Profile
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Stories
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
